Skip to main content

Table 1 Study characteristics

From: Evaluating dose response from flexible dose clinical trials

  Study A
N* = 234
Study B
N* = 172
Disease state Bipolar I mania Schizophrenia
Duration of study 12 weeks 28 weeks
Visit intervals 2 weeks 2–4 weeks
Dosages, mg/day Olanzapine (5, 10, 15, 20) Olanzapine (10, 15, 20)
Starting dose, mg/day Olanzapine (15) Olanzapine (15)
Gender, % female 60.2 35.1
Age in years, mean (SD) 39.9 (13.2) 36.2 (10.7)
Symptom severity, mean (SD) YMRS total, 30.7 (7.5) PANSS total, 96 (16.6)
  1. *Olanzapine-treatment arm only